Current regulatory frameworks limit the use of lecanemab and donanemab to patients who present with a clinical syndrome of MCI or mild dementia consistent with AD, have biomarker-confirmed amyloid pathology (and, in some protocols, tau staging), and show acceptable cerebrovascular risk and brain MRI profiles [38,39,40]. Here, MAPT is linked to dementia.